Novel fragments of clavulanate observed in the structure of the class A β-lactamase from Bacillus licheniformis BS3

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2379-2387

  Power, Pablo ^a   Mercuri, Paola ^b   Herman, Raphaël ^b   Kerff, Frédéric ^b   Gutkind, Gabriel ^a   Dive, Georges ^b   Galleni, Moreno ^b   Charlier, Paulette ^b   Sauvage, Eric ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

lactamase inactivation; Bacterial resistance; Clavulanate

Indexed keywords

BETA LACTAMASE; CARBOXYLIC ACID; CLAVULANIC ACID; ENAMINE; ETHANE; IMINE; ION; PENTAN 3 ONE 5 OL ACID; PENTANE; UNCLASSIFIED DRUG;

ARTICLE; BACILLUS LICHENIFORMIS; DECARBOXYLATION; ENZYME ACTIVE SITE; HYDROLYSIS; KINETICS; MASS SPECTROMETRY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STEADY STATE; X RAY CRYSTALLOGRAPHY;

BACILLUS; BETA-LACTAMASES; CLAVULANIC ACID; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HYDROLYSIS; KINETICS; MASS SPECTROMETRY; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84866627325     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks231     Document Type: Article

References (37)

1. Frère JM, Nguyen-Distéche M, Coyette J et al. Mode of action: interaction with the penicillin-binding-proteins. In: Page MI, ed. The Chemistry of β-Lactams. Glasgow, UK: Blackie Academic and Professional, Chapman & Hall, 1992; 148-97.
2. Tomasz A. The mechanism of the irreversible antimicrobial effects of penicillin. Ann Rev Microbiol 1979; 33: 113-37.
3. Frère JM. β-Lactamases and bacterial resistance to antibiotics. Mol Microbiol 1995; 16: 385-95.
4. Ghuysen JM. Serine β-lactamases and penicillin-binding proteins. Annu Rev Microbiol 1991; 45: 37-67.
5. Waley SG. β-Lactamase: mechanism of action. In: Page MI, ed. The Chemistry of b-Lactams. Glasgow, UK: Blackie Academic and Professional, Chapman & Hall, 1992; 198-228.
6. Rotschafer JC, Ostergaard BE. Combination β-lactam and β-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition. Am J Health Syst Pharm 1995; 52 Suppl 2: S15-22.
7. Charnas RL, Knowles JR. Inactivation of RTEM β-lactamase from Escherichia coli by clavulanic acid and 9-deoxyclavulanic acid. Biochemistry 1981; 20: 3214-9.
8. Therrien C, Levesque RC. Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol Rev 2000; 24: 251-62.
9. Padayatti PS, Helfand MS, Totir MA et al. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 β-lactamase. J Biol Chem 2005; 280: 34900-7.
10. Cartwright SJ, Coulson AF. Active site of staphylococcal β-lactamase. Philos Trans R Soc Lond B Biol Sci 1980; 289: 370-2.
11. Chen CC, Herzberg O. Inhibition of β-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies. J Mol Biol 1992; 224: 1103-13.
12. Knowles JR. Penicillin resistance: the chemistry of β-lactamase inhibition. Acc Chem Res 1985; 18: 97-104.
13. Imtiaz U, Manavathu EK, Lerner SA et al. Critical hydrogen bonding by serine 235 for cephalosporinase activity of TEM-1 β-lactamase. Antimicrob Agents Chemother 1993; 37: 2438-42.
14. Moews PC, Knox JR, Dideberg O et al. β-Lactamase of Bacillus licheniformis 749/C at 2 Åresolution. Proteins 1990; 7: 156-71.
15. Brown RP, Aplin RT, Schofield CJ. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 1996; 35: 12421-32.
16. Ledent P, Duez C, Vanhove M et al. Unexpected influence of a C-terminal-fused His-tag on the processing of an enzyme and on the kinetic and folding parameters. FEBS Lett 1997; 413: 194-6.
17. Leslie AGW. Molecular data processing. Crystallogr Comput 1991; 5: 50-61.
18. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994; 50: 760-3.
19. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53: 240-55.
20. Painter J, Merritt EA. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 2006; 62: 439-50.
21. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60: 2126-32.
22. Fonzé E, Vanhove M, Dive G et al. Crystal structures of the Bacillus licheniformis BS3 class A β-lactamase and of the acyl-enzyme adduct formed with cefoxitin. Biochemistry 2002; 41: 1877-85.
23. Shimamura T, Ibuka A, Fushinobu S et al. Acyl-intermediate structures of the extended-spectrum class A β-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin. J Biol Chem 2002; 277: 46601-8.
24. Tremblay LW, Hugonnet JE, Blanchard JS. Structure of the covalent adduct formed between Mycobacterium tuberculosis β-lactamase and clavulanate. Biochemistry 2008; 47: 5312-6.
25. Helfand MS, Totir MA, Carey MP et al. Following the reactions of mechanism-based inhibitors with β-lactamase by Raman crystallography. Biochemistry 2003; 42: 13386-92.
26. Sulton D, Pagan-Rodriguez D, Zhou X et al. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J Biol Chem 2005; 280: 35528-36.
27. Matagne A, Ghuysen MF, Frère JM. Interactions between activesite-serine β-lactamases and mechanism-based inactivators: a kinetic study and an overview. Biochem J 1993; 295: 705-11.
28. Charnas RL, Fisher J, Knowles JR. Chemical studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry 1978; 17: 2185-9.
29. Perez-Llarena F, Martin JF, Galleni M et al. The bla gene of the cephamycin cluster of Streptomyces clavuligerus encodes a class A β-lactamase of low enzymatic activity. J Bacteriol 1997; 179: 6035-40.
30. Frère JM, Dormans C, Lenzini VM et al. Interaction of clavulanate with the β-lactamases of Streptomyces albus G and Actinomadura R39. Biochem J 1982; 207: 429-36.
31. Bethel CR, Taracila M, Shyr T et al. Exploring the inhibition of CTX-M-9 by β-lactamase inhibitors and carbapenems. Antimicrob Agents Chemother 2011; 55: 3465-75.
32. Galleni M, Franceschini N, Quinting B et al. Use of the chromosomal class A β-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory b-lactam compounds. Antimicrob Agents Chemother 1994; 38: 1608-14.
33. Delaire M, Lenfant F, Labia R et al. Site-directed mutagenesis on TEM-1 β-lactamase: role of Glu166 in catalysis and substrate binding. Protein Eng 1991; 4: 805-10.
34. Farzaneh S, Chaibi EB, Peduzzi J et al. Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrob Agents Chemother 1996; 40: 2434-6.
35. Saves I, Burlet-Schiltz O, Swaren P et al. The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid. J Biol Chem 1995; 270: 18240-5.
36. Belaaouaj A, Lapoumeroulie C, Canica MM et al. Nucleotide sequences of the genes coding for the TEM-like β-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiol Lett 1994; 120: 75-80.
37. Bermudes H, Jude F, Chaibi EB et al. Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived β-lactamase in a clinical isolate of Klebsiella oxytoca. Antimicrob Agents Chemother 1999; 43: 1657-61.